Internal Medicine Department
The Hematology - Oncology Division
Research Information (For Health Care Professionals)
Oncology Research Office - 915.545.6510 Fax- 915.545.0966
Cancer Clinical Trials. We have numerous active clinical trials and many under review currently in our local IRB . We have received a $1.5 million CPRIT grant to establish a “Clinical Cancer Research Core Facility”. http://www.cprit.state.tx.us/images/uploads/cfsa_slate_11022011.pdf (Please keep checking the web site for updates on upcoming trials)
Breast Cancer Trial for Early Stage Breast Cancer
|
- Title S0221-Phase III Trial of Continuous Schedule AC + G Vs. 2 Week Schedule AC, Followed by Paclitaxel Given Either Every 2 Weeks or Weekly for 12 Weeks as Post-Operative Adjuvant Therapy in Node-Positive or High-Risk Node Negative Breast Cancer.This randomized phase III trial is studying the best schedule of adjuvant chemotherapy (dose dense or weekly).
- Status : Active
|
Breast Cancer Trial for Locally Advanced and Inflammatory Breast Cancer:
|
- Title: S0800- Phase II Randomized Study of Neoadjuvant Paclitaxel Albumin-Stabilized Nanoparticle Formulation, Doxorubicin Hydrochloride, Cyclophosphamide, and Pegfilgrastim With Versus Without Bevacizumab in Women With HER2/neu-Negative Inflammatory or Locally Advanced Breast Cancer.This randomized phase II trial is studying paclitaxel albumin-stabilized nanoparticle formulation, doxorubicin, cyclophosphamide, and pegfilgrastim to compare how well they work when given with or without bevacizumab in treating women with inflammatory or locally advanced breast cancer.
National Principal Investigator: Zeina Nahleh MD
Status: Active nationwide, under review in El Paso
Age: Adult
Sponsor: National Cancer Institute
Protocol IDs: SWOG-S0800, S0800, NCT00856492
NCI Grant Number- CA32102
ClinicalTrials.gov
|
Breast Cancer Trials for Metastatic Breast cancer
|
- Title:” AUY922 with Lapatinib and Letrozole for ER+, HER2+Advanced Breast cancer “.This study is studying whether administering infusions of the novel agent AUY922 with hormonal therapy (letrozole) and oral targeted drug (lapatinib) will benefit patients with advanced breast cancer known as ER+ HER2 +. All drugs are free.
Principal Investigator: Zeina Nahleh MD
Status: Active
Age: Adult
Sponsor: industry
Protocol IDs: CAUY922ZN11, NCT01361945
ClinicalTrials.gov
Title :” A Phase III Randomized, Double-blind, Placebo-controlled Trial Comparing Capecitabine Plus Sorafenib Versus Capecitabine Plus Placebo in the Treatment of Locally Advanced or Metastatic HER2-Negative Breast Cancer”.This study is an international trial offering a combination of the 2 oral agents and comparing its efficacy to single agent capecitabine (all drugs provided free)
Local Principal Investigator: Zeina Nahleh MD
Status: Active
Age: Adult
Sponsor: industry, global
Title: "Banking of Tissue and Establishing Continuous Cell Lines and Xenografts from Neoplasia", in collaboration with South Plains Oncology Consortium (SPONC) and the Texas Cancer Research Biobank (TCRB)
This study is banking tumor tissue and matching it with normal cells enables studies to improve the understanding of cancer biology, and to develop improved diagnostic, prognostic , and therapeutic approaches.
Status: Active
Age: Adult
|
For More Information, visit the National Cancer Institute's education page about cancer clinical trials at:
http://www.cancer.gov/clinicaltrials/
Research Infomation (For Patients)
Oncology Research Office - 915.545.6510 Fax- 915.545.0966
Cancer Clinical Trials. We have numerous active clinical trials currently accepting patients and some are still under review by our local IRB (Please keep checking the website for updates on upcoming trials)
Breast Cancer Trial for Early Stage Breast Cancer
|
- Title S0221-Phase III Trial of Continuous Schedule AC + G Vs. 2 Week Schedule AC, Followed by Paclitaxel Given Either Every 2 Weeks or Weekly for 12 Weeks as Post-Operative Adjuvant Therapy in Node-Positive or High-Risk Node Negative Breast Cancer. This randomized phase III trial is studying the best schedule of adjuvant chemotherapy (dose dense or weekly)
- Status: Active
|
Breast Cancer Trial for Locally Advanced and Inflammatory Breast Cancer: S0800
|
- This randomized phase II trial is studying a special formulation of paclitaxel (albumin-stabilized nanoparticle formulation), in addition to standard chemotherapy agents (doxorubicin, cyclophosphamide) and compare how well they work when given with or without bevacizumab, a biologic drug that starves the tumor and prevents its blood supply formation, in treating women with inflammatory or locally advanced breast cancer.
National Principal Investigator: Zeina Nahleh MD
Status: Active nationwide, under review in locally
Age: Adult
Sponsor: National Cancer Institute and SWOG
ClinicalTrials.gov
|
Breast Cancer Trial for Advanced Breast cancer using a novel agent AUY 922 in addition to standard treatment
|
- This study is evaluating whether administering infusions of the novel biologic drug AUY922 with hormonal therapy (letrozole) and oral targeted drug (lapatinib) will benefit patients with advanced breast cancer known as ER+ HER2 + above what is known as the benefit from standard treatment with letrozole and lapatinib alone. Drugs are free.
Principal Investigator: Zeina Nahleh MD
Status: approved, under review
Age: Adult
ClinicalTrials.gov
|
Breast Cancer Trial for Advanced Breast Cancer using a standard chemotherapy drug given orally (by mouth) with or without a novel biologic drug, sorafenib.
|
- This study is evaluating whether adding a novel agent sorafenib to standard chemotherapy, capecitabine (both drugs given by mouth) is more effective compared to capecitabine alone. Drugs are free.
Local Principal Investigator: Zeina Nahleh MD
Status: Active
Age: Adult
Sponsor: Industry, International Trial
|
For More Information, visit the National Cancer Institute's education page about cancer clinical trials at:
http://www.cancer.gov/clinicaltrials/
